Stelara Biosimilar SYSA1902 Psoriasis Clinical Equivalence

Summary of the Article:‍ SYSA1902 (Ustekinumab Biosimilar) for Moderate to Severe Plaque⁢ Psoriasis

This⁢ article details a study evaluating SYSA1902, a biosimilar⁢ to ⁣ Stelara (ustekinumab),‍ in ⁢the treatment of moderate to severe plaque psoriasis in Chinese ⁤patients.

Key Findings:

* Efficacy: SYSA1902 demonstrated equivalence to Stelara in terms of betterment in Psoriasis Area and Severity ⁤Index (PASI) at week 12. The mean percentage change from baseline in PASI was 86.4% for SYSA1902 and 84.7% for Stelara.
* PASI 75 response: ⁣A high percentage of patients in both groups achieved PASI 75 at week 12: 83.3% with ⁢SYSA1902 and 79.3% with Stelara.
* Safety: The rate of treatment-emergent adverse events (TEAEs) was similar between the two groups⁤ (89.3% for SYSA1902‍ and 85.6% ⁣for Stelara), and most were mild to moderate. ⁣ Upper respiratory tract infection was the most common TEAE.
* Limitation: The study’s findings may not be generalizable to populations outside⁢ of Chinese patients.

background Facts (from the article):

* Ustekinumab is a monoclonal antibody used to treat psoriasis, psoriatic arthritis, and inflammatory bowel disease. It works by targeting IL-12 and IL-23.
* It ⁣is indeed⁤ FDA-approved for moderate to severe plaque psoriasis in patients 6 years or older,and for active‍ psoriatic arthritis.
* it has⁤ also been used “off-label” for other inflammatory conditions.
* Biosimilars are highly similar, but ⁣not⁤ identical, copies⁣ of already-approved biologic⁣ drugs.

Potential Impact:

SYSA1902 could become another biosimilar option to Stelara, potentially increasing access and lowering costs for patients with moderate to severe plaque psoriasis.